Other Services

This Service

A database built with INDRA combining content from numerous readers and databases. This page allows you to curate the loaded statements. For more information please see the manual.

This Project

INDRA is developed by indralabs, a part of the Harvard Medical School Laboratory of Systems Pharmacology.

This project, indra_db, is also developed by the indralab team. For more information on how we procure our sources, you can go here. This work was funded by ARO grant W911NF‐15‐1‐0544 under the DARPA Communicating with Computers program.

IndraLab

Statements

UCHL1 increases the amount of SNCA. 3 / 3

| 3

➶

reach

"In this line, in vitro studies using a crude cell-free system where alpha-synuclein was conjugated to histidine tagged ubiquitin revealed that the addition of UCHL-3 had little effect, whereas the add[MISSING/INVALID CREDENTIALS: limited to 200 char for Elsevier]"

16380264

➶

reach

"Reduction of UCH-L1 (M) in cell culture models of alpha-synuclein toxicity by treatment with a farnesyltransferase inhibitor (FTI-277) reduces alpha-synuclein levels and increases cell viability."

19261853

➶

reach

"Chemical inhibition of UCHL1 by farnesylation may reduce alpha-synuclein levels and improve neuronal cell viability in cellular models of alpha-synuclein-associated toxicity for PD."

28765971

Our Sources:

INDRA allows us to combine the results from a multitude of sources. In particular, the INDRA Database draws on the following...

Other Services

This Service

This Project

IndraLab

Statements

UCHL1 increases the amount of SNCA. 3 / 3

Our Sources:

Databases

Reading